Evaluation of the Argos System to Estimate Cardiac Output
Evaluation of the Argos System to Estimate Cardiac Output in Critically Ill Patients
The goal of this observational study is to evaluate the reliability of the Argos system to track changes in cardiac output in critically ill patients. The main question it aims to answer is:
Does cardiac output changes induced by fluid administration or changes in norepinephrine dosage can be tracked by the Argos system, compared to transpulmonary thermodilution device.
研究概览
详细说明
In patients with acute circulatory failure, hemodynamic monitoring including cardiac index (CI) assessment is recommended for most severe patients. Transpulmonary thermodilution (TPTD) is one of the methods that are recommended for this purpose, in particular because it is considered as reliable in this type of patients. The PiCCO2 system (Pulsion Medical Systems, Getinge, Feldkirchen, Germany) relies on TPTD method and associate two methods to measure CI. On the one hand, TPTD is considered as one of the gold standards for CI evaluation (CITPTD). On the other hand, pulse contour analysis calculates stroke volume from the waveform of the systolic part of the arterial pressure curve (CIpwa). The way this estimation is performed and it is regularly re-evaluated differs among the devices that are available on the market. This estimation of CIpwa is calibrated when TPTD is performed. Thus, it allows a real-time pulse contour derived CI assessment, which is very precise. However, TPTD system are considered invasive, expensive and are not available in all settings.
The Argos monitor (Retia Medical, Valhalla, USA) uses the so-called multi-beat analysis (MBA) to estimate CI after analyzing the arterial pressure waveform over periods of multiple heartbeats (up to 20) and scaling CI estimations to biometric data. The algorithm estimates the theoretical central arterial blood pressure waveform using MBA, minimizing and avoiding the cofounding effect of the wave reflection phenomena. Based on this central arterial blood pressure waveform and biometric patient data, the system estimates cardiac output. The Argos monitor has a second advantage. It simply connects to the analogue output of the blood pressure signal from a compatible multi-parameter monitor and needs no additional specific pressure sensor. During cardiac surgery, the Argos monitor showed reasonable agreement and trending ability compared to the pulmonary artery catheter. However, in patients after cardiac surgery, including those with low cardiac output and arrhythmia, CI estimated by the device was not interchangeable with the continuous thermodilution method via a PAC.
The primary objective of the study is to evaluate the reliability of the Argos system to track changes of CI induced by changes in norepinephrine or fluid administration, compared to CITPTD in critically ill patients.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Christopher Lai, MD, PhD
- 电话号码:12633816521
- 邮箱:christopher.lai@aphp.fr
学习地点
-
-
-
Le Kremlin-Bicêtre、法国
- 招聘中
- Bicetre Hospital
-
接触:
- Christopher Lai
- 电话号码:2633816521
- 邮箱:christopher.lai@aphp.fr
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
Patients with shock defined by one sign of hypoperfusion:
- systolic arterial pressure <90mmHg
- mean arterial pressure <65mmHg
- prolonged capillary refill time >3 sec
- mottling score > 2
- urine output < 0.1 mL/kg/h
描述
Inclusion Criteria:
- Age ≥18 years old
- Hospitalisation in intensive care
- Haemodynamic monitoring with transpulmonary thermodilution already in place
Hemodynamic intervention deemed necessary by the clinician in charge of the patient
- Administration of a fluid bolus
- Change in norepinephrine dosage or performance of a vasopressor test
Exclusion Criteria:
- Pregnancy
- Other therapeutic modification during volume expansion or the vasopressor test
- Refusal to participate by relatives of the patient or the patient himself or herself
- Non availability of investigators
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
patients with shock
Patients with shock defined by one sign of hypoperfusion:
|
Giving a fluid bolus of 500mL of normal saline (NaCl 0.9%)
brief, transient increase in norepinephrine to achieve a 15mmHg increase in mean arterial pressure and evaluates if tissue perfusion improves
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
To compare the changes in cardiac output provided by the Argos system induced by changes in norepinephrine or fluid bolus, compared to cardiac output provided by the transpulmonary thermodilution device in critically ill patients.
大体时间:1 hour (before and after intervention)
|
1 hour (before and after intervention)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Accuracy of the Argos system
大体时间:1 hour (before and after intervention)
|
To evaluate the accuracy of the Argos system to measure absolute values of cardiac output compared to transpulmonary thermodilution
|
1 hour (before and after intervention)
|
|
Precision of the Argos system
大体时间:1 hour (before and after intervention)
|
To evaluate the precision and least significant change of cardiac output provided by the Argos system
|
1 hour (before and after intervention)
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.